3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
6
Glioblastoma
5
Esophageal Neoplasms
3
Childhood Brain Neoplasm
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic carcinoma, familial
1
Pancreatic Intraductal Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Neoplasms
1
Lung Carcinoma Metastatic in the Brain
1
Liver Neoplasms
1
Liver Cirrhosis
1
Ischemic Stroke
1
Hypoxia
1
Hemorrhagic Stroke
1
Head and Neck Neoplasms
1
Glioma
1
Cranial Nerve Diseases
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Interventions
Cyclophosphamide
16
Temozolomide
13
Vincristine
10
Irinotecan
8
Melphalan
7
Doxorubicin
7
Topotecan
6
Granulocyte Colony-Stimulating Factor
6
Busulfan
6
fludarabine
5
cabozantinib
5
Etoposide
5
Drug Therapy
5
liposomal doxorubicin
4
Sirolimus
4
Ifosfamide
4
Filgrastim
4
regorafenib
3
pegfilgrastim
3
irinotecan sucrosofate
3
fludarabine phosphate
3
Zoledronic Acid
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Cisplatin
3
Bone Marrow Transplantation
3
Albumin-Bound Paclitaxel
3
pegylated granulocyte colony-stimulating factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma, Ewing
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts